JP2014505696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505696A5 JP2014505696A5 JP2013551000A JP2013551000A JP2014505696A5 JP 2014505696 A5 JP2014505696 A5 JP 2014505696A5 JP 2013551000 A JP2013551000 A JP 2013551000A JP 2013551000 A JP2013551000 A JP 2013551000A JP 2014505696 A5 JP2014505696 A5 JP 2014505696A5
- Authority
- JP
- Japan
- Prior art keywords
- morpholin
- methyl
- indol
- purine
- purin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 34
- 239000011780 sodium chloride Substances 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 32
- 150000002431 hydrogen Chemical class 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- -1 amino, hydroxy, carboxy Chemical group 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 239000005977 Ethylene Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 235000011962 puddings Nutrition 0.000 claims description 6
- CBSLYDYRSSZKJQ-UHFFFAOYSA-N 4-(2-morpholin-4-yl-8-phenyl-7H-purin-6-yl)morpholine Chemical compound C1COCCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=CC=CC=3)C2=N1 CBSLYDYRSSZKJQ-UHFFFAOYSA-N 0.000 claims description 4
- 206010053643 Neurodegenerative disease Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- BYPBFDASESWSQG-HUUCEWRRSA-N (3R)-4-[8-(1H-indol-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-7H-purin-6-yl]-3-methylmorpholine Chemical compound C[C@@H]1COCCN1C1=NC(N2[C@@H](COCC2)C)=C(N=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 BYPBFDASESWSQG-HUUCEWRRSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- RTASTCNILVYNIH-KBPBESRZSA-N (1S,4S)-5-[8-(1H-indol-4-yl)-2-morpholin-4-yl-7H-purin-6-yl]-2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C([C@]1(OC[C@]2([H])C1)[H])N2C(C=1N=C(NC=1N=1)C=2C=3C=CNC=3C=CC=2)=NC=1N1CCOCC1 RTASTCNILVYNIH-KBPBESRZSA-N 0.000 claims description 2
- VKDGYMMHLINOOQ-HOTGVXAUSA-N (1S,4S)-5-[8-(1H-indol-6-yl)-2-morpholin-4-yl-7H-purin-6-yl]-2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C([C@]1(OC[C@]2([H])C1)[H])N2C(C=1N=C(NC=1N=1)C=2C=C3NC=CC3=CC=2)=NC=1N1CCOCC1 VKDGYMMHLINOOQ-HOTGVXAUSA-N 0.000 claims description 2
- WJLUFTVOQWSVGA-CVEARBPZSA-N (3R)-4-[6-(1H-indol-4-yl)-2-[(3S)-3-methylmorpholin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2[C@@H](COCC2)C)=C(C=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 WJLUFTVOQWSVGA-CVEARBPZSA-N 0.000 claims description 2
- BEVPZSCSVBGHBS-CQSZACIVSA-N (3R)-4-[8-(1H-indol-4-yl)-2-morpholin-4-yl-7H-purin-6-yl]-3-methylmorpholine Chemical compound C[C@@H]1COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C=3C=CNC=3C=CC=1)N2 BEVPZSCSVBGHBS-CQSZACIVSA-N 0.000 claims description 2
- YHBIGTGZWVBCGN-CQSZACIVSA-N (3R)-4-[8-(1H-indol-4-yl)-6-morpholin-4-yl-7H-purin-2-yl]-3-methylmorpholine Chemical compound C[C@@H]1COCCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 YHBIGTGZWVBCGN-CQSZACIVSA-N 0.000 claims description 2
- UOJYDROKRRUPFT-HUUCEWRRSA-N (3R)-4-[8-(1H-indol-6-yl)-2-[(3R)-3-methylmorpholin-4-yl]-7H-purin-6-yl]-3-methylmorpholine Chemical compound C[C@@H]1COCCN1C1=NC(N2[C@@H](COCC2)C)=C(N=C(N2)C=3C=C4NC=CC4=CC=3)C2=N1 UOJYDROKRRUPFT-HUUCEWRRSA-N 0.000 claims description 2
- GKWDEEDUAOXXQS-CQSZACIVSA-N (3R)-4-[8-(1H-indol-6-yl)-2-morpholin-4-yl-7H-purin-6-yl]-3-methylmorpholine Chemical compound C[C@@H]1COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C=C3NC=CC3=CC=1)N2 GKWDEEDUAOXXQS-CQSZACIVSA-N 0.000 claims description 2
- KQHGRDFADPRLCV-HUUCEWRRSA-N (3R)-4-[8-(2,3-dihydro-1H-indol-4-yl)-2-[(3R)-3-methylmorpholin-4-yl]-7H-purin-6-yl]-3-methylmorpholine Chemical compound C[C@@H]1COCCN1C1=NC(N2[C@@H](COCC2)C)=C(N=C(N2)C=3C=4CCNC=4C=CC=3)C2=N1 KQHGRDFADPRLCV-HUUCEWRRSA-N 0.000 claims description 2
- KQHGRDFADPRLCV-CABCVRRESA-N (3R)-4-[8-(2,3-dihydro-1H-indol-4-yl)-2-[(3S)-3-methylmorpholin-4-yl]-7H-purin-6-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2[C@@H](COCC2)C)=C(N=C(N2)C=3C=4CCNC=4C=CC=3)C2=N1 KQHGRDFADPRLCV-CABCVRRESA-N 0.000 claims description 2
- YLOCTAWZZXJSJN-KBPBESRZSA-N (3S)-3-methyl-4-[2-[(3S)-3-methylmorpholin-4-yl]-8-(1H-pyrrolo[2,3-b]pyridin-4-yl)-7H-purin-6-yl]morpholine Chemical compound C[C@H]1COCCN1C1=NC(N2[C@H](COCC2)C)=C(N=C(N2)C=3C=4C=CNC=4N=CC=3)C2=N1 YLOCTAWZZXJSJN-KBPBESRZSA-N 0.000 claims description 2
- LYQJKASYVKVEEA-AWEZNQCLSA-N (3S)-4-[2-(4,4-difluoropiperidin-1-yl)-8-(1H-indol-4-yl)-7H-purin-6-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2CCC(F)(F)CC2)=NC2=C1N=C(C=1C=3C=CNC=3C=CC=1)N2 LYQJKASYVKVEEA-AWEZNQCLSA-N 0.000 claims description 2
- BYPBFDASESWSQG-GJZGRUSLSA-N (3S)-4-[8-(1H-indol-4-yl)-2-[(3S)-3-methylmorpholin-4-yl]-7H-purin-6-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2[C@H](COCC2)C)=C(N=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 BYPBFDASESWSQG-GJZGRUSLSA-N 0.000 claims description 2
- BEVPZSCSVBGHBS-AWEZNQCLSA-N (3S)-4-[8-(1H-indol-4-yl)-2-morpholin-4-yl-7H-purin-6-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C=3C=CNC=3C=CC=1)N2 BEVPZSCSVBGHBS-AWEZNQCLSA-N 0.000 claims description 2
- YHBIGTGZWVBCGN-AWEZNQCLSA-N (3S)-4-[8-(1H-indol-4-yl)-6-morpholin-4-yl-7H-purin-2-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 YHBIGTGZWVBCGN-AWEZNQCLSA-N 0.000 claims description 2
- UOJYDROKRRUPFT-GJZGRUSLSA-N (3S)-4-[8-(1H-indol-6-yl)-2-[(3S)-3-methylmorpholin-4-yl]-7H-purin-6-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2[C@H](COCC2)C)=C(N=C(N2)C=3C=C4NC=CC4=CC=3)C2=N1 UOJYDROKRRUPFT-GJZGRUSLSA-N 0.000 claims description 2
- GKWDEEDUAOXXQS-AWEZNQCLSA-N (3S)-4-[8-(1H-indol-6-yl)-2-morpholin-4-yl-7H-purin-6-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C=C3NC=CC3=CC=1)N2 GKWDEEDUAOXXQS-AWEZNQCLSA-N 0.000 claims description 2
- ILDHZDODQYEWAJ-MLCCFXAWSA-N 1-[3-[6-[(3S)-3-methylmorpholin-4-yl]-2-morpholin-4-yl-7H-purin-8-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(C=2NC3=NC(=NC(=C3N=2)N2[C@H](COCC2)C)N2CCOCC2)=C1 ILDHZDODQYEWAJ-MLCCFXAWSA-N 0.000 claims description 2
- UEYSRNFLKQULSV-AWEZNQCLSA-N 1-[8-(1H-indol-4-yl)-6-[(3S)-3-methylmorpholin-4-yl]-7H-purin-2-yl]piperidin-4-ol Chemical compound C[C@H]1COCCN1C1=NC(N2CCC(O)CC2)=NC2=C1N=C(C=1C=3C=CNC=3C=CC=1)N2 UEYSRNFLKQULSV-AWEZNQCLSA-N 0.000 claims description 2
- HNTBJDRLVQNBKM-ZDUSSCGKSA-N 2-methoxy-5-[6-[(3S)-3-methylmorpholin-4-yl]-2-morpholin-4-yl-7H-purin-8-yl]benzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC=C1C1=NC2=C(N3[C@H](COCC3)C)N=C(N3CCOCC3)N=C2N1 HNTBJDRLVQNBKM-ZDUSSCGKSA-N 0.000 claims description 2
- LHDDJVLSHMJNRL-UHFFFAOYSA-N 3-(2,4-dimorpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol Chemical compound OC1=CC=CC(C=2NC3=NC(=NC(=C3C=2)N2CCOCC2)N2CCOCC2)=C1 LHDDJVLSHMJNRL-UHFFFAOYSA-N 0.000 claims description 2
- FMZONAXKIRVOKC-UHFFFAOYSA-N 3-(2,6-dimorpholin-4-yl-7H-purin-8-yl)aniline Chemical compound NC1=CC=CC(C=2NC3=NC(=NC(=C3N=2)N2CCOCC2)N2CCOCC2)=C1 FMZONAXKIRVOKC-UHFFFAOYSA-N 0.000 claims description 2
- VFXYAIGDRFKLJB-UHFFFAOYSA-N 3-(2,6-dimorpholin-4-yl-7H-purin-8-yl)phenol Chemical compound OC1=CC=CC(C=2NC3=NC(=NC(=C3N=2)N2CCOCC2)N2CCOCC2)=C1 VFXYAIGDRFKLJB-UHFFFAOYSA-N 0.000 claims description 2
- UOSMHXGISNKBLD-OKILXGFUSA-N 3-[2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-6-morpholin-4-yl-7H-purin-8-yl]aniline Chemical compound C1[C@@H](C)O[C@@H](C)CN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=C(N)C=CC=3)C2=N1 UOSMHXGISNKBLD-OKILXGFUSA-N 0.000 claims description 2
- VZMACCZUZHFZEC-OKILXGFUSA-N 3-[2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-6-morpholin-4-yl-7H-purin-8-yl]phenol Chemical compound C1[C@@H](C)O[C@@H](C)CN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=C(O)C=CC=3)C2=N1 VZMACCZUZHFZEC-OKILXGFUSA-N 0.000 claims description 2
- KRYOJFZBIQYOHN-UHFFFAOYSA-N 3-[8-(1H-indol-4-yl)-2-morpholin-4-yl-7H-purin-6-yl]-8-oxa-3-azabicyclo[3.2.1]octane Chemical compound C1C(O2)CCC2CN1C(C=1N=C(NC=1N=1)C=2C=3C=CNC=3C=CC=2)=NC=1N1CCOCC1 KRYOJFZBIQYOHN-UHFFFAOYSA-N 0.000 claims description 2
- HGVRBIGKHBXUFG-QQFBHYJXSA-N 3-[8-(1H-indol-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]-7H-purin-2-yl]-8-oxa-3-azabicyclo[3.2.1]octane Chemical compound C[C@@H]1COCCN1C1=NC(N2CC3CCC(O3)C2)=NC2=C1N=C(C=1C=3C=CNC=3C=CC=1)N2 HGVRBIGKHBXUFG-QQFBHYJXSA-N 0.000 claims description 2
- HGVRBIGKHBXUFG-FHERZECASA-N 3-[8-(1H-indol-4-yl)-6-[(3S)-3-methylmorpholin-4-yl]-7H-purin-2-yl]-8-oxa-3-azabicyclo[3.2.1]octane Chemical compound C[C@H]1COCCN1C1=NC(N2CC3CCC(O3)C2)=NC2=C1N=C(C=1C=3C=CNC=3C=CC=1)N2 HGVRBIGKHBXUFG-FHERZECASA-N 0.000 claims description 2
- DVPYIFZQYGTELJ-NNGSBXSVSA-N 3-[8-(1H-indol-6-yl)-6-[(3S)-3-methylmorpholin-4-yl]-7H-purin-2-yl]-8-oxa-3-azabicyclo[3.2.1]octane Chemical compound C[C@H]1COCCN1C1=NC(N2CC3CCC(O3)C2)=NC2=C1N=C(C=1C=C3NC=CC3=CC=1)N2 DVPYIFZQYGTELJ-NNGSBXSVSA-N 0.000 claims description 2
- LQZSVKMDKITWSJ-UHFFFAOYSA-N 4-[2-morpholin-4-yl-8-(1H-pyrrolo[3,2-b]pyridin-6-yl)-7H-purin-6-yl]morpholine Chemical compound C1COCCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=C4NC=CC4=NC=3)C2=N1 LQZSVKMDKITWSJ-UHFFFAOYSA-N 0.000 claims description 2
- ZEKDZZGWTRXRNM-UHFFFAOYSA-N 4-[6-(1H-indol-4-yl)-2-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(N2CCOCC2)=C(C=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 ZEKDZZGWTRXRNM-UHFFFAOYSA-N 0.000 claims description 2
- SJCXYQGBFKEGFT-UHFFFAOYSA-N 4-[8-(1H-indazol-4-yl)-2-morpholin-4-yl-7H-purin-6-yl]morpholine Chemical compound C1COCCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=4C=NNC=4C=CC=3)C2=N1 SJCXYQGBFKEGFT-UHFFFAOYSA-N 0.000 claims description 2
- KRXHAQBOIOEJDX-UHFFFAOYSA-N 4-[8-(1H-indol-4-yl)-2-(4-methoxypiperidin-1-yl)-7H-purin-6-yl]morpholine Chemical compound C1CC(OC)CCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 KRXHAQBOIOEJDX-UHFFFAOYSA-N 0.000 claims description 2
- VJJPFNTUJZFMLU-UHFFFAOYSA-N 4-[8-(1H-indol-4-yl)-2-morpholin-4-yl-7H-purin-6-yl]-3,3-dimethylmorpholine Chemical compound CC1(C)COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C=3C=CNC=3C=CC=1)N2 VJJPFNTUJZFMLU-UHFFFAOYSA-N 0.000 claims description 2
- IEEZPCDISDDNHG-UHFFFAOYSA-N 4-[8-(1H-indol-4-yl)-2-morpholin-4-yl-7H-purin-6-yl]morpholine Chemical compound C1COCCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 IEEZPCDISDDNHG-UHFFFAOYSA-N 0.000 claims description 2
- VYRPJNSRBPXZAM-UHFFFAOYSA-N 4-[8-(1H-indol-6-yl)-2-morpholin-4-yl-7H-purin-6-yl]-3,3-dimethylmorpholine Chemical compound CC1(C)COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C=C3NC=CC3=CC=1)N2 VYRPJNSRBPXZAM-UHFFFAOYSA-N 0.000 claims description 2
- OYYVNOMYSQOASK-UHFFFAOYSA-N 4-[8-(1H-indol-6-yl)-2-morpholin-4-yl-7H-purin-6-yl]morpholine Chemical compound C1COCCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=C4NC=CC4=CC=3)C2=N1 OYYVNOMYSQOASK-UHFFFAOYSA-N 0.000 claims description 2
- RUNAXPMSDKPKIK-UHFFFAOYSA-N 4-[8-(2-methyl-1H-indol-4-yl)-2-morpholin-4-yl-7H-purin-6-yl]morpholine Chemical compound C1=CC=C2NC(C)=CC2=C1C(NC1=N2)=NC1=C(N1CCOCC1)N=C2N1CCOCC1 RUNAXPMSDKPKIK-UHFFFAOYSA-N 0.000 claims description 2
- HBEQHZQYKVYGEC-STQMWFEESA-N 5-[2,6-bis[(3S)-3-methylmorpholin-4-yl]-7H-purin-8-yl]-1,3-dihydrobenzimidazol-2-one Chemical compound C[C@H]1COCCN1C1=NC(N2[C@H](COCC2)C)=C(N=C(N2)C=3C=C4NC(=O)NC4=CC=3)C2=N1 HBEQHZQYKVYGEC-STQMWFEESA-N 0.000 claims description 2
- MUZINCWNYBPUBQ-UHFFFAOYSA-N 8-[8-(1H-indol-4-yl)-2-morpholin-4-yl-7H-purin-6-yl]-3-oxa-8-azabicyclo[3.2.1]octane Chemical compound C1CC2COCC1N2C(C=1N=C(NC=1N=1)C=2C=3C=CNC=3C=CC=2)=NC=1N1CCOCC1 MUZINCWNYBPUBQ-UHFFFAOYSA-N 0.000 claims description 2
- AWTMEHOJPLEHIB-UHFFFAOYSA-N 8-[8-(1H-indol-6-yl)-2-morpholin-4-yl-7H-purin-6-yl]-3-oxa-8-azabicyclo[3.2.1]octane Chemical compound C1CC2COCC1N2C(C=1N=C(NC=1N=1)C=2C=C3NC=CC3=CC=2)=NC=1N1CCOCC1 AWTMEHOJPLEHIB-UHFFFAOYSA-N 0.000 claims description 2
- IDDGBSMMVIQCFB-UHFFFAOYSA-N N-[3-(2,6-dimorpholin-4-yl-7H-purin-8-yl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2NC3=NC(=NC(=C3N=2)N2CCOCC2)N2CCOCC2)=C1 IDDGBSMMVIQCFB-UHFFFAOYSA-N 0.000 claims description 2
- OBWFZOFNDPVEAB-UHFFFAOYSA-N N-[3-(2,6-dimorpholin-4-yl-7H-purin-8-yl)phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2NC3=NC(=NC(=C3N=2)N2CCOCC2)N2CCOCC2)=C1 OBWFZOFNDPVEAB-UHFFFAOYSA-N 0.000 claims description 2
- JGGFNICMQLLJTB-UHFFFAOYSA-N OC1=CC=CC=C1C1=NC2=C(N3CCOCC3)N=C(N3CCOCC3)N=C2N1 Chemical compound OC1=CC=CC=C1C1=NC2=C(N3CCOCC3)N=C(N3CCOCC3)N=C2N1 JGGFNICMQLLJTB-UHFFFAOYSA-N 0.000 claims description 2
- UXJUBJNTKJPGOA-UHFFFAOYSA-N [2-(2,6-dimorpholin-4-yl-7H-purin-8-yl)phenyl]methanol Chemical compound OCC1=CC=CC=C1C1=NC2=C(N3CCOCC3)N=C(N3CCOCC3)N=C2N1 UXJUBJNTKJPGOA-UHFFFAOYSA-N 0.000 claims description 2
- MGDXERJAXBSHNC-GASCZTMLSA-N [2-[2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-6-morpholin-4-yl-7H-purin-8-yl]phenyl]methanol Chemical compound C1[C@@H](C)O[C@@H](C)CN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C(=CC=CC=3)CO)C2=N1 MGDXERJAXBSHNC-GASCZTMLSA-N 0.000 claims description 2
- CWQWCVCZQYDZSG-ZDUSSCGKSA-N [2-fluoro-5-[6-[(3S)-3-methylmorpholin-4-yl]-2-morpholin-4-yl-7H-purin-8-yl]phenyl]methanol Chemical compound C[C@H]1COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C=C(CO)C(F)=CC=1)N2 CWQWCVCZQYDZSG-ZDUSSCGKSA-N 0.000 claims description 2
- NNJBEJBNMSIGPU-UHFFFAOYSA-N [3-(2,6-dimorpholin-4-yl-7H-purin-8-yl)phenyl]methanamine Chemical compound NCC1=CC=CC(C=2NC3=NC(=NC(=C3N=2)N2CCOCC2)N2CCOCC2)=C1 NNJBEJBNMSIGPU-UHFFFAOYSA-N 0.000 claims description 2
- HHASSGIDQRQXQL-UHFFFAOYSA-N [3-(2,6-dimorpholin-4-yl-7H-purin-8-yl)phenyl]methanol Chemical compound OCC1=CC=CC(C=2NC3=NC(=NC(=C3N=2)N2CCOCC2)N2CCOCC2)=C1 HHASSGIDQRQXQL-UHFFFAOYSA-N 0.000 claims description 2
- MXVIMDXYEAFHOH-ZIAGYGMSSA-N [3-[2,6-bis[(3R)-3-methylmorpholin-4-yl]-7H-purin-8-yl]-4-fluorophenyl]methanol Chemical compound C[C@@H]1COCCN1C1=NC(N2[C@@H](COCC2)C)=C(N=C(N2)C=3C(=CC=C(CO)C=3)F)C2=N1 MXVIMDXYEAFHOH-ZIAGYGMSSA-N 0.000 claims description 2
- RQQODQBXZJNYJU-GJZGRUSLSA-N [3-[2,6-bis[(3S)-3-methylmorpholin-4-yl]-7H-purin-8-yl]-5-methoxyphenyl]methanol Chemical compound COC1=CC(CO)=CC(C=2NC3=NC(=NC(=C3N=2)N2[C@H](COCC2)C)N2[C@H](COCC2)C)=C1 RQQODQBXZJNYJU-GJZGRUSLSA-N 0.000 claims description 2
- JVNUUIKGGAZSOR-ZDUSSCGKSA-N [4-chloro-3-[6-[(3S)-3-methylmorpholin-4-yl]-2-morpholin-4-yl-7H-purin-8-yl]phenyl]methanol Chemical compound C[C@H]1COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C(=CC=C(CO)C=1)Cl)N2 JVNUUIKGGAZSOR-ZDUSSCGKSA-N 0.000 claims description 2
- SXNLIWCUBYOYCB-GJZGRUSLSA-N [5-[2,6-bis[(3S)-3-methylmorpholin-4-yl]-7H-purin-8-yl]-2-methoxyphenyl]methanol Chemical compound C1=C(CO)C(OC)=CC=C1C1=NC2=C(N3[C@H](COCC3)C)N=C(N3[C@H](COCC3)C)N=C2N1 SXNLIWCUBYOYCB-GJZGRUSLSA-N 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229940079593 drugs Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 0 Cc(c(*)c1*)c(*)c(O)c1N Chemical compound Cc(c(*)c1*)c(*)c(O)c1N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
Description
以下に、本願の当初の特許請求の範囲に記載された発明を付記する。The invention described in the scope of the original claims of the present application will be added below.
[1] 式(I)[1] Formula (I)
[式中、[Where:
Xは、NまたはCHであり、X is N or CH;
RR
11
は、Is
〔式中、[Where,
RR
1818
およびRAnd R
2222
は、独立して、水素、ハロゲン、ヒドロキシまたはヒドロキシ−CIs independently hydrogen, halogen, hydroxy or hydroxy-C
1−31-3
アルキル−であり、Alkyl-,
RR
1919
およびRAnd R
2121
は、独立して、水素、アミノ、ヒドロキシ、カルボキシ、CIndependently represents hydrogen, amino, hydroxy, carboxy, C
1−31-3
アルコキシ、アミノ−CAlkoxy, amino-C
1−31-3
アルキル−、CAlkyl-, C
1−31-3
アルキル−C(=O)−NH−、CAlkyl-C (═O) —NH—, C
1−31-3
アルキル−S(=O)Alkyl-S (= O)
mm
−NH−またはヒドロキシ−C-NH- or hydroxy-C
1−31-3
アルキル−であり、Alkyl-,
mは、0、1または2であり、m is 0, 1 or 2;
RR
2020
は、水素、ハロゲンまたはCIs hydrogen, halogen or C
1−31-3
アルコキシである。〕Alkoxy. ]
であるか、またはOr
RR
11
は、Is
〔式中、[Where,
RR
2323
は、水素またはメチルであり、Is hydrogen or methyl;
RR
2424
は、水素、オキソまたはCIs hydrogen, oxo or C
1−31-3
アルキルである。〕Alkyl. ]
で示される基からなる群から選択され、Selected from the group consisting of
RR
22
、R, R
33
、R, R
44
、R, R
55
、R, R
66
、R, R
77
、R, R
88
、R, R
99
、R, R
1010
、R, R
1111
、R, R
1212
、R, R
1313
、,
RR
1414
、R, R
1515
、R, R
1616
およびRAnd R
1717
は、独立して、水素またはメチルであるか、Are independently hydrogen or methyl,
または、ROr R
22
およびRAnd R
88
は一体となって、エチレン架橋を形成するか、Together form an ethylene bridge,
または、ROr R
22
およびRAnd R
66
は一体となって、メチレン架橋を形成するか、Together to form a methylene bridge,
または、ROr R
1212
およびRAnd R
1414
は一体となって、エチレン架橋を形成し、Together form an ethylene bridge,
Yは、O、CHRY is O, CHR
2525
またはCROr CR
2626
RR
2727
(ここで、R(Where R
2525
は、ヒドロキシまたはCIs hydroxy or C
1−31-3
アルコキシであり、RAlkoxy and R
2626
およびRAnd R
2727
は、独立して、水素またはハロゲンである)である。]Are independently hydrogen or halogen. ]
で示される化合物(ただし、式(I)の化合物は、2,6−ジ−モルホリン−4−イル−8−フェニル−9H−プリン以外である)、またはその薬学的に許容される塩。Wherein the compound of formula (I) is other than 2,6-di-morpholin-4-yl-8-phenyl-9H-purine, or a pharmaceutically acceptable salt thereof.
[2] 式(I)[2] Formula (I)
[式中、[Where:
Xは、NまたはCHであり、X is N or CH;
RR
11
は、Is
〔式中、[Where,
RR
1818
およびRAnd R
2222
は、独立して、水素、ハロゲン、ヒドロキシまたはヒドロキシ−CIs independently hydrogen, halogen, hydroxy or hydroxy-C
1−31-3
アルキル−であり、Alkyl-,
RR
1919
およびRAnd R
2121
は、独立して、水素、アミノ、ヒドロキシ、カルボキシ、CIndependently represents hydrogen, amino, hydroxy, carboxy, C
1−31-3
アルコキシ、アミノ−CAlkoxy, amino-C
1−31-3
アルキル−、CAlkyl-, C
1−31-3
アルキル−C(=O)−NH−、CAlkyl-C (═O) —NH—, C
1−31-3
アルキル−S(=O)Alkyl-S (= O)
mm
−NH−またはヒドロキシ−C-NH- or hydroxy-C
1−31-3
アルキル−であり、Alkyl-,
mは、0、1または2であり、m is 0, 1 or 2;
RR
2020
は、水素、ハロゲンまたはCIs hydrogen, halogen or C
1−31-3
アルコキシである。〕Alkoxy. ]
であるか、またはOr
RR
11
は、Is
〔式中、[Where,
RR
2323
は、水素またはメチルであり、Is hydrogen or methyl;
RR
2424
は、水素、オキソまたはCIs hydrogen, oxo or C
1−31-3
アルキルである。〕Alkyl. ]
で示される基からなる群から選択され、Selected from the group consisting of
RR
22
、R, R
33
、R, R
44
、R, R
55
、R, R
66
、R, R
77
、R, R
88
、R, R
99
、R, R
1010
、R, R
1111
、R, R
1212
、R, R
1313
、R, R
1414
、R, R
1515
、R, R
1616
およびRAnd R
1717
は、独立して、水素またはメチルであるか、Are independently hydrogen or methyl,
または、ROr R
55
およびRAnd R
66
は、一体となって、エチレン架橋を形成し、Together form an ethylene bridge,
Yは、O、CHRY is O, CHR
2525
またはCROr CR
2626
RR
2727
(ここで、R(Where R
2525
は、ヒドロキシまたはCIs hydroxy or C
1−31-3
アルコキシであり、RAlkoxy and R
2626
およびRAnd R
2727
は、独立して、水素またはハロゲンである)である。]Are independently hydrogen or halogen. ]
で示される化合物(ただし、式(I)の化合物は、2,6−ジ−モルホリン−4−イル−8−フェニル−9H−プリン以外である)、またはその薬学的に許容される塩。Wherein the compound of formula (I) is other than 2,6-di-morpholin-4-yl-8-phenyl-9H-purine, or a pharmaceutically acceptable salt thereof.
[3] XがNである、[1]または[2]に記載の化合物、またはその薬学的に許容される塩。[3] The compound according to [1] or [2], wherein X is N, or a pharmaceutically acceptable salt thereof.
[4] XがCHである、[1]または[2]に記載の化合物、またはその薬学的に許容される塩。[4] The compound according to [1] or [2], wherein X is CH, or a pharmaceutically acceptable salt thereof.
[5] R[5] R
11
が、But,
〔式中、[Where,
RR
1818
およびRAnd R
2222
が、独立して、水素、ハロゲン、ヒドロキシまたはヒドロキシ−CAre independently hydrogen, halogen, hydroxy or hydroxy-C
1−31-3
アルキル−であり、Alkyl-,
RR
1919
およびRAnd R
2121
が、独立して、水素、アミノ、ヒドロキシ、カルボキシ、CIndependently of hydrogen, amino, hydroxy, carboxy, C
1−31-3
アルコキシ、アミノ−CAlkoxy, amino-C
1−31-3
アルキル−、CAlkyl-, C
1−31-3
アルキル−C(=O)−NH−、CAlkyl-C (═O) —NH—, C
1−31-3
アルキル−S(=O)Alkyl-S (= O)
mm
−NH−またはヒドロキシ−C-NH- or hydroxy-C
1−31-3
アルキル−であり、Alkyl-,
mが、0、1または2であり、m is 0, 1 or 2;
RR
2020
が、水素、ハロゲンまたはCIs hydrogen, halogen or C
1−31-3
アルコキシである。〕Alkoxy. ]
である、[1]ないし[4]のいずれかに記載の化合物、またはその薬学的に許容される塩。The compound according to any one of [1] to [4], or a pharmaceutically acceptable salt thereof.
[6] R[6] R
1818
、R, R
1919
、R, R
2020
、R, R
2121
およびRAnd R
2222
の少なくとも1つが水素ではない、[5]に記載の化合物、またはその薬学的に許容される塩。The compound according to [5], wherein at least one of is not hydrogen, or a pharmaceutically acceptable salt thereof.
[7] R[7] R
11
が、But,
〔式中、[Where,
RR
2323
は、水素またはメチルであり、Is hydrogen or methyl;
RR
2424
は、水素、オキソまたはCIs hydrogen, oxo or C
1−31-3
アルキルである。〕Alkyl. ]
で示される基からなる群から選択される、[1]ないし[4]のいずれかに記載の化合物、またはその薬学的に許容される塩。The compound according to any one of [1] to [4], or a pharmaceutically acceptable salt thereof, selected from the group consisting of groups represented by:
[8] YがOである、[1]ないし[7]のいずれかに記載の化合物、またはその薬学的に許容される塩。[8] The compound according to any one of [1] to [7], wherein Y is O, or a pharmaceutically acceptable salt thereof.
[9] YがCHR[9] Y is CHR
2626
またはCROr CR
2727
RR
2828
である、[1]ないし[7]のいずれかに記載の化合物、またはその薬学的に許容される塩。The compound according to any one of [1] to [7], or a pharmaceutically acceptable salt thereof.
[10] 3−[2−((2S,6R)−2,6−ジメチル−モルホリン−4−イル)−6−モルホリン−4−イル−9H−プリン−8−イル]−フェノール;[10] 3- [2-((2S, 6R) -2,6-dimethyl-morpholin-4-yl) -6-morpholin-4-yl-9H-purin-8-yl] -phenol;
3−(2,4−ジモルホリノ−7H−ピロロ[2,3−d]ピリミジン−6−イル)フェノール;3- (2,4-dimorpholino-7H-pyrrolo [2,3-d] pyrimidin-6-yl) phenol;
2,6−ビス−((S)−3−メチル−モルホリン−4−イル)−8−(1H−ピロロ[2,3−b]ピリジン−4−イル)−9H−プリン;2,6-bis-((S) -3-methyl-morpholin-4-yl) -8- (1H-pyrrolo [2,3-b] pyridin-4-yl) -9H-purine;
{2−フルオロ−5−[6−((S)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン−8−イル]−フェニル}−メタノール;{2-fluoro-5- [6-((S) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purin-8-yl] -phenyl} -methanol;
2−(4,4−ジフルオロ−ピペリジン−1−イル)−8−(1H−インドール−4−イル)−6−((S)−3−メチル−モルホリン−4−イル)−9H−プリン;2- (4,4-difluoro-piperidin-1-yl) -8- (1H-indol-4-yl) -6-((S) -3-methyl-morpholin-4-yl) -9H-purine;
5−[2,6−ビス−((S)−3−メチル−モルホリン−4−イル)−9H−プリン−8−イル]−1,3−ジヒドロ−ベンゾイミダゾール−2−オン;5- [2,6-bis-((S) -3-methyl-morpholin-4-yl) -9H-purin-8-yl] -1,3-dihydro-benzimidazol-2-one;
{5−[2,6−ビス−((S)−3−メチル−モルホリン−4−イル)−9H−プリン−8−イル]−2−メトキシ−フェニル}−メタノール;{5- [2,6-bis-((S) -3-methyl-morpholin-4-yl) -9H-purin-8-yl] -2-methoxy-phenyl} -methanol;
8−(1H−インドール−4−イル)−2−モルホリン−4−イル−6−(8−オキサ−3−アザ−ビシクロ[3.2.1]オクト−3−イル)−9H−プリン;8- (1H-indol-4-yl) -2-morpholin-4-yl-6- (8-oxa-3-aza-bicyclo [3.2.1] oct-3-yl) -9H-purine;
2−メトキシ−5−[6−((S)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン−8−イル]−安息香酸;2-methoxy-5- [6-((S) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purin-8-yl] -benzoic acid;
{4−クロロ−3−[6−((S)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン−8−イル]−フェニル}−メタノール;{4-chloro-3- [6-((S) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purin-8-yl] -phenyl} -methanol;
3−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−ベンジルアミン;3- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -benzylamine;
1−{3−[6−((S)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン−8−イル]−フェニル}−エタノール;1- {3- [6-((S) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purin-8-yl] -phenyl} -ethanol;
2,6−ジ−モルホリン−4−イル−8−(1H−ピロロ[3,2−b]ピリジン−6−イル)−9H−プリン;2,6-di-morpholin-4-yl-8- (1H-pyrrolo [3,2-b] pyridin-6-yl) -9H-purine;
8−(1H−インドール−6−イル)−2,6−ビス−((S)−3−メチル−モルホリン−4−イル)−9H−プリン;8- (1H-indol-6-yl) -2,6-bis-((S) -3-methyl-morpholin-4-yl) -9H-purine;
8−(1H−インドール−4−イル)−2,6−ビス−((R)−3−メチル−モルホリン−4−イル)−9H−プリン;8- (1H-indol-4-yl) -2,6-bis-((R) -3-methyl-morpholin-4-yl) -9H-purine;
1−[8−(1H−インドール−4−イル)−6−((S)−3−メチル−モルホリン−4−イル)−9H−プリン−2−イル]−ピペリジン−4−オール;1- [8- (1H-indol-4-yl) -6-((S) -3-methyl-morpholin-4-yl) -9H-purin-2-yl] -piperidin-4-ol;
{3−[2,6−ビス−((S)−3−メチル−モルホリン−4−イル)−9H−プリン−8−イル]−5−メトキシ−フェニル}−メタノール;{3- [2,6-bis-((S) -3-methyl-morpholin-4-yl) -9H-purin-8-yl] -5-methoxy-phenyl} -methanol;
8−(1H−インドール−4−イル)−2−((R)−3−メチル−モルホリン−4−イル)−6−((S)−3−メチル−モルホリン−4−イル)−9H−プリン;8- (1H-Indol-4-yl) -2-((R) -3-methyl-morpholin-4-yl) -6-((S) -3-methyl-morpholin-4-yl) -9H- Pudding;
{3−[2,6−ビス−((R)−3−メチル−モルホリン−4−イル)−9H−プリン−8−イル]−4−フルオロ−フェニル}−メタノール;{3- [2,6-bis-((R) -3-methyl-morpholin-4-yl) -9H-purin-8-yl] -4-fluoro-phenyl} -methanol;
8−(1H−インドール−4−イル)−6−((R)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン;8- (1H-indol-4-yl) -6-((R) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purine;
8−(1H−インドール−6−イル)−6−((R)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン;8- (1H-indol-6-yl) -6-((R) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purine;
8−(1H−インドール−4−イル)−2,6−ビス−((S)−3−メチル−モルホリン−4−イル)−9H−プリン;8- (1H-indol-4-yl) -2,6-bis-((S) -3-methyl-morpholin-4-yl) -9H-purine;
8−(1H−インドール−4−イル)−6−((S)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン;8- (1H-indol-4-yl) -6-((S) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purine;
8−(1H−インドール−6−イル)−6−((S)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン;8- (1H-indol-6-yl) -6-((S) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purine;
8−(1H−インドール−4−イル)−2−(4−メトキシ−ピペリジン−1−イル)−6−モルホリン−4−イル−9H−プリン;8- (1H-indol-4-yl) -2- (4-methoxy-piperidin-1-yl) -6-morpholin-4-yl-9H-purine;
8−(1H−インドール−4−イル)−2,6−ジ−モルホリン−4−イル−9H−プリン;8- (1H-indol-4-yl) -2,6-di-morpholin-4-yl-9H-purine;
8−(1H−インダゾール−4−イル)−2,6−ジ−モルホリン−4−イル−9H−プリン;8- (1H-indazol-4-yl) -2,6-di-morpholin-4-yl-9H-purine;
8−(1H−インドール−6−イル)−2,6−ジ−モルホリン−4−イル−9H−プリン;8- (1H-indol-6-yl) -2,6-di-morpholin-4-yl-9H-purine;
3−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−フェニルアミン;3- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -phenylamine;
N−[3−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−フェニル]−アセトアミド;N- [3- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -phenyl] -acetamide;
8−(2−メチル−1H−インドール−4−イル)−2,6−ジ−モルホリン−4−イル−9H−プリン;8- (2-methyl-1H-indol-4-yl) -2,6-di-morpholin-4-yl-9H-purine;
3−[2−((2S,6R)−2,6−ジメチル−モルホリン−4−イル)−6−モルホリン−4−イル−9H−プリン−8−イル]−フェニルアミン;3- [2-((2S, 6R) -2,6-dimethyl-morpholin-4-yl) -6-morpholin-4-yl-9H-purin-8-yl] -phenylamine;
N−[3−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−フェニル]−メタンスルホンアミド;N- [3- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -phenyl] -methanesulfonamide;
{2−[2−((2S,6R)−2,6−ジメチル−モルホリン−4−イル)−6−モルホリン−4−イル−9H−プリン−8−イル]−フェニル}−メタノール;{2- [2-((2S, 6R) -2,6-dimethyl-morpholin-4-yl) -6-morpholin-4-yl-9H-purin-8-yl] -phenyl} -methanol;
[2−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−フェニル]−メタノール;[2- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -phenyl] -methanol;
3−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−フェノール;3- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -phenol;
[3−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−フェニル]−メタノール;[3- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -phenyl] -methanol;
2−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−フェノール;2- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -phenol;
6−(3,3−ジメチル−モルホリン−4−イル)−8−(1H−インドール−6−イル)−2−モルホリン−4−イル−9H−プリン;6- (3,3-Dimethyl-morpholin-4-yl) -8- (1H-indol-6-yl) -2-morpholin-4-yl-9H-purine;
6−(3,3−ジメチル−モルホリン−4−イル)−8−(1H−インドール−4−イル)−2−モルホリン−4−イル−9H−プリン;6- (3,3-Dimethyl-morpholin-4-yl) -8- (1H-indol-4-yl) -2-morpholin-4-yl-9H-purine;
8−(2,3−ジヒドロ−1H−インドール−4−イル)−2−((S)−3−メチル−モルホリン−4−イル)−6−((R)−3−メチル−モルホリン−4−イル)−9H−プリン;8- (2,3-Dihydro-1H-indol-4-yl) -2-((S) -3-methyl-morpholin-4-yl) -6-((R) -3-methyl-morpholine-4 -Yl) -9H-purine;
8−(2,3−ジヒドロ−1H−インドール−4−イル)−2,6−ビス−((R)−3−メチル−モルホリン−4−イル)−9H−プリン;8- (2,3-dihydro-1H-indol-4-yl) -2,6-bis-((R) -3-methyl-morpholin-4-yl) -9H-purine;
8−(1H−インドール−4−イル)−2−((S)−3−メチル−モルホリン−4−イル)−6−((R)−3−メチル−モルホリン−4−イル)−9H−プリン;8- (1H-Indol-4-yl) -2-((S) -3-methyl-morpholin-4-yl) -6-((R) -3-methyl-morpholin-4-yl) -9H- Pudding;
8−(1H−インドール−6−イル)−2−((S)−3−メチル−モルホリン−4−イル)−6−((R)−3−メチル−モルホリン−4−イル)−9H−プリン;8- (1H-Indol-6-yl) -2-((S) -3-methyl-morpholin-4-yl) -6-((R) -3-methyl-morpholin-4-yl) -9H- Pudding;
8−(1H−インドール−6−イル)−2,6−ビス−((R)−3−メチル−モルホリン−4−イル)−9H−プリン;8- (1H-indol-6-yl) -2,6-bis-((R) -3-methyl-morpholin-4-yl) -9H-purine;
8−(1H−インドール−4−イル)−6−((R)−3−メチル−モルホリン−4−イル)−2−(8−オキサ−3−アザ−ビシクロ[3.2.1]オクト−3−イル)−9H−プリン;8- (1H-Indol-4-yl) -6-((R) -3-methyl-morpholin-4-yl) -2- (8-oxa-3-aza-bicyclo [3.2.1] oct -3-yl) -9H-purine;
8−(1H−インドール−4−イル)−2−((R)−3−メチル−モルホリン−4−イル)−6−モルホリン−4−イル−9H−プリン;8- (1H-indol-4-yl) -2-((R) -3-methyl-morpholin-4-yl) -6-morpholin-4-yl-9H-purine;
8−(1H−インドール−6−イル)−2−モルホリン−4−イル−6−(1S,4S)−2−オキサ−5−アザ−ビシクロ[2.2.1]ヘプト−5−イル−9H−プリン;8- (1H-Indol-6-yl) -2-morpholin-4-yl-6- (1S, 4S) -2-oxa-5-aza-bicyclo [2.2.1] hept-5-yl- 9H-purine;
8−(1H−インドール−4−イル)−2−((S)−3−メチル−モルホリン−4−イル)−6−モルホリン−4−イル−9H−プリン;8- (1H-indol-4-yl) -2-((S) -3-methyl-morpholin-4-yl) -6-morpholin-4-yl-9H-purine;
8−(1H−インドール−4−イル)−2−モルホリン−4−イル−6−(1S,4S)−2−オキサ−5−アザ−ビシクロ[2.2.1]ヘプト−5−イル−9H−プリン;8- (1H-Indol-4-yl) -2-morpholin-4-yl-6- (1S, 4S) -2-oxa-5-aza-bicyclo [2.2.1] hept-5-yl- 9H-purine;
8−(1H−インドール−6−イル)−6−((S)−3−メチル−モルホリン−4−イル)−2−(8−オキサ−3−アザ−ビシクロ[3.2.1]オクト−3−イル)−9H−プリン;8- (1H-Indol-6-yl) -6-((S) -3-methyl-morpholin-4-yl) -2- (8-oxa-3-aza-bicyclo [3.2.1] oct -3-yl) -9H-purine;
8−(1H−インドール−4−イル)−6−((S)−3−メチル−モルホリン−4−イル)−2−(8−オキサ−3−アザ−ビシクロ[3.2.1]オクト−3−イル)−9H−プリン;8- (1H-Indol-4-yl) -6-((S) -3-methyl-morpholin-4-yl) -2- (8-oxa-3-aza-bicyclo [3.2.1] oct -3-yl) -9H-purine;
8−(1H−インドール−6−イル)−2−モルホリン−4−イル−6−(3−オキサ−8−アザ−ビシクロ[3.2.1]オクト−8−イル)−9H−プリン;8- (1H-indol-6-yl) -2-morpholin-4-yl-6- (3-oxa-8-aza-bicyclo [3.2.1] oct-8-yl) -9H-purine;
8−(1H−インドール−4−イル)−2−モルホリン−4−イル−6−(3−オキサ−8−アザ−ビシクロ[3.2.1]オクト−8−イル)−9H−プリン;8- (1H-indol-4-yl) -2-morpholin-4-yl-6- (3-oxa-8-aza-bicyclo [3.2.1] oct-8-yl) -9H-purine;
6−(1H−インドール−4−イル)−4−((R)−3−メチル−モルホリン−4−イル)−2−((S)−3−メチル−モルホリン−4−イル)−7H−ピロロ[2,3−d]ピリミジン;6- (1H-Indol-4-yl) -4-((R) -3-methyl-morpholin-4-yl) -2-((S) -3-methyl-morpholin-4-yl) -7H- Pyrrolo [2,3-d] pyrimidine;
6−(1H−インドール−4−イル)−2,4−ジ−モルホリン−4−イル−7H−ピロロ[2,3−d]ピリミジン;6- (1H-indol-4-yl) -2,4-di-morpholin-4-yl-7H-pyrrolo [2,3-d] pyrimidine;
から選択される、[1]または[2]に記載の化合物、またはその薬学的に許容される塩。The compound according to [1] or [2], or a pharmaceutically acceptable salt thereof, selected from:
[11] 医薬としての使用のための、[1]ないし[10]のいずれかに記載の化合物、またはその薬学的に許容される塩。[11] The compound according to any one of [1] to [10] or a pharmaceutically acceptable salt thereof for use as a medicament.
[12] 癌または神経変性障害の処置または予防における使用のための、[1]ないし[10]のいずれかに記載の化合物、またはその薬学的に許容される塩。[12] The compound according to any one of [1] to [10] or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of cancer or a neurodegenerative disorder.
[13] [1]ないし[10]のいずれかに記載の化合物、またはその薬学的に許容される塩、および薬学的に許容される賦形剤、希釈剤または担体を含む、医薬組成物。[13] A pharmaceutical composition comprising the compound according to any one of [1] to [10], or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, diluent or carrier.
[14] 癌または神経変性障害の処置または予防のための医薬の製造を目的とする、[1]ないし[10]のいずれかに記載の化合物、またはその薬学的に許容される塩の使用。[14] Use of the compound according to any one of [1] to [10] or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing cancer or a neurodegenerative disorder.
[15] 同時または連続投与のための、治療的有効量の[1]ないし[10]のいずれかに記載の化合物、またはその薬学的に許容される塩、および第2の薬物を含む、組合せ剤。[15] A combination comprising a therapeutically effective amount of a compound according to any one of [1] to [10], or a pharmaceutically acceptable salt thereof, and a second drug for simultaneous or sequential administration Agent.
Claims (19)
[式中、
Xは、NまたはCHであり、
R1は、
〔式中、
R18およびR22は、独立して、水素、ハロゲン、ヒドロキシまたはヒドロキシ−C1−3アルキル−であり、
R19およびR21は、独立して、水素、アミノ、ヒドロキシ、カルボキシ、C1−3アルコキシ、アミノ−C1−3アルキル−、C1−3アルキル−C(=O)−NH−、C1−3アルキル−S(=O)m−NH−またはヒドロキシ−C1−3アルキル−であり、
mは、0、1または2であり、
R20は、水素、ハロゲンまたはC1−3アルコキシである。〕
であるか、または
R1は、
〔式中、
R23は、水素またはメチルであり、
R24は、水素、オキソまたはC1−3アルキルである。〕
で示される基からなる群から選択され、
R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、
R14、R15、R16およびR17は、独立して、水素またはメチルであるか、
または、R2およびR8は一体となって、エチレン架橋を形成するか、
または、R2およびR6は一体となって、メチレン架橋を形成するか、
または、R12およびR14は一体となって、エチレン架橋を形成し、
Yは、O、CHR25またはCR26R27(ここで、R25は、ヒドロキシまたはC1−3アルコキシであり、R26およびR27は、独立して、水素またはハロゲンである)である。]
で示される化合物(ただし、式(I)の化合物は、2,6−ジ−モルホリン−4−イル−8−フェニル−9H−プリン以外である)、またはその薬学的に許容される塩。 Formula (I)
[Where:
X is N or CH;
R 1 is
[Where,
R 18 and R 22 are independently hydrogen, halogen, hydroxy or hydroxy-C 1-3 alkyl-;
R 19 and R 21 are independently hydrogen, amino, hydroxy, carboxy, C 1-3 alkoxy, amino-C 1-3 alkyl-, C 1-3 alkyl-C (═O) —NH—, C 1-3 alkyl-S (═O) m —NH— or hydroxy-C 1-3 alkyl-
m is 0, 1 or 2;
R 20 is hydrogen, halogen or C 1-3 alkoxy. ]
Or R 1 is
[Where,
R 23 is hydrogen or methyl;
R 24 is hydrogen, oxo or C 1-3 alkyl. ]
Selected from the group consisting of
R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 ,
R 14 , R 15 , R 16 and R 17 are independently hydrogen or methyl,
Or R 2 and R 8 together form an ethylene bridge,
Or R 2 and R 6 together form a methylene bridge,
Or R 12 and R 14 together form an ethylene bridge;
Y is O, CHR 25, or CR 26 R 27, where R 25 is hydroxy or C 1-3 alkoxy, and R 26 and R 27 are independently hydrogen or halogen. ]
Wherein the compound of formula (I) is other than 2,6-di-morpholin-4-yl-8-phenyl-9H-purine, or a pharmaceutically acceptable salt thereof.
[式中、
Xは、NまたはCHであり、
R1は、
〔式中、
R18およびR22は、独立して、水素、ハロゲン、ヒドロキシまたはヒドロキシ−C1−3アルキル−であり、
R19およびR21は、独立して、水素、アミノ、ヒドロキシ、カルボキシ、C1−3アルコキシ、アミノ−C1−3アルキル−、C1−3アルキル−C(=O)−NH−、C1−3アルキル−S(=O)m−NH−またはヒドロキシ−C1−3アルキル−であり、
mは、0、1または2であり、
R20は、水素、ハロゲンまたはC1−3アルコキシである。〕
であるか、または
R1は、
〔式中、
R23は、水素またはメチルであり、
R24は、水素、オキソまたはC1−3アルキルである。〕
で示される基からなる群から選択され、
R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16およびR17は、独立して、水素またはメチルであるか、
または、R5およびR6は、一体となって、エチレン架橋を形成し、
Yは、O、CHR25またはCR26R27(ここで、R25は、ヒドロキシまたはC1−3アルコキシであり、R26およびR27は、独立して、水素またはハロゲンである)である。]
で示される化合物(ただし、式(I)の化合物は、2,6−ジ−モルホリン−4−イル−8−フェニル−9H−プリン以外である)、またはその薬学的に許容される塩。 Formula (I)
[Where:
X is N or CH;
R 1 is
[Where,
R 18 and R 22 are independently hydrogen, halogen, hydroxy or hydroxy-C 1-3 alkyl-;
R 19 and R 21 are independently hydrogen, amino, hydroxy, carboxy, C 1-3 alkoxy, amino-C 1-3 alkyl-, C 1-3 alkyl-C (═O) —NH—, C 1-3 alkyl-S (═O) m —NH— or hydroxy-C 1-3 alkyl-
m is 0, 1 or 2;
R 20 is hydrogen, halogen or C 1-3 alkoxy. ]
Or R 1 is
[Where,
R 23 is hydrogen or methyl;
R 24 is hydrogen, oxo or C 1-3 alkyl. ]
Selected from the group consisting of
R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 and R 17 are independent. Either hydrogen or methyl,
Or R 5 and R 6 together form an ethylene bridge;
Y is O, CHR 25, or CR 26 R 27, where R 25 is hydroxy or C 1-3 alkoxy, and R 26 and R 27 are independently hydrogen or halogen. ]
Wherein the compound of formula (I) is other than 2,6-di-morpholin-4-yl-8-phenyl-9H-purine, or a pharmaceutically acceptable salt thereof.
〔式中、
R18およびR22が、独立して、水素、ハロゲン、ヒドロキシまたはヒドロキシ−C1−3アルキル−であり、
R19およびR21が、独立して、水素、アミノ、ヒドロキシ、カルボキシ、C1−3アルコキシ、アミノ−C1−3アルキル−、C1−3アルキル−C(=O)−NH−、C1−3アルキル−S(=O)m−NH−またはヒドロキシ−C1−3アルキル−であり、
mが、0、1または2であり、
R20が、水素、ハロゲンまたはC1−3アルコキシである。〕
である、請求項1ないし4のいずれか一項に記載の化合物、またはその薬学的に許容される塩。 R 1 is
[Where,
R 18 and R 22 are independently hydrogen, halogen, hydroxy or hydroxy-C 1-3 alkyl-;
R 19 and R 21 are independently hydrogen, amino, hydroxy, carboxy, C 1-3 alkoxy, amino-C 1-3 alkyl-, C 1-3 alkyl-C (═O) —NH—, C 1-3 alkyl-S (═O) m —NH— or hydroxy-C 1-3 alkyl-
m is 0, 1 or 2;
R 20 is hydrogen, halogen or C 1-3 alkoxy. ]
The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof.
〔式中、
R23は、水素またはメチルであり、
R24は、水素、オキソまたはC1−3アルキルである。〕
で示される基からなる群から選択される、請求項1ないし4のいずれか一項に記載の化合物、またはその薬学的に許容される塩。 R 1 is
[Where,
R 23 is hydrogen or methyl;
R 24 is hydrogen, oxo or C 1-3 alkyl. ]
The compound as described in any one of Claims 1 thru | or 4 selected from the group which consists of group shown by these, or its pharmaceutically acceptable salt.
3−(2,4−ジモルホリノ−7H−ピロロ[2,3−d]ピリミジン−6−イル)フェノール;
2,6−ビス−((S)−3−メチル−モルホリン−4−イル)−8−(1H−ピロロ[2,3−b]ピリジン−4−イル)−9H−プリン;
{2−フルオロ−5−[6−((S)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン−8−イル]−フェニル}−メタノール;
2−(4,4−ジフルオロ−ピペリジン−1−イル)−8−(1H−インドール−4−イル)−6−((S)−3−メチル−モルホリン−4−イル)−9H−プリン;
5−[2,6−ビス−((S)−3−メチル−モルホリン−4−イル)−9H−プリン−8−イル]−1,3−ジヒドロ−ベンゾイミダゾール−2−オン;
{5−[2,6−ビス−((S)−3−メチル−モルホリン−4−イル)−9H−プリン−8−イル]−2−メトキシ−フェニル}−メタノール;
8−(1H−インドール−4−イル)−2−モルホリン−4−イル−6−(8−オキサ−3−アザ−ビシクロ[3.2.1]オクト−3−イル)−9H−プリン;
2−メトキシ−5−[6−((S)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン−8−イル]−安息香酸;
{4−クロロ−3−[6−((S)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン−8−イル]−フェニル}−メタノール;
3−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−ベンジルアミン;
1−{3−[6−((S)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン−8−イル]−フェニル}−エタノール;
2,6−ジ−モルホリン−4−イル−8−(1H−ピロロ[3,2−b]ピリジン−6−イル)−9H−プリン;
8−(1H−インドール−6−イル)−2,6−ビス−((S)−3−メチル−モルホリン−4−イル)−9H−プリン;
8−(1H−インドール−4−イル)−2,6−ビス−((R)−3−メチル−モルホリン−4−イル)−9H−プリン;
1−[8−(1H−インドール−4−イル)−6−((S)−3−メチル−モルホリン−4−イル)−9H−プリン−2−イル]−ピペリジン−4−オール;
{3−[2,6−ビス−((S)−3−メチル−モルホリン−4−イル)−9H−プリン−8−イル]−5−メトキシ−フェニル}−メタノール;
8−(1H−インドール−4−イル)−2−((R)−3−メチル−モルホリン−4−イル)−6−((S)−3−メチル−モルホリン−4−イル)−9H−プリン;
{3−[2,6−ビス−((R)−3−メチル−モルホリン−4−イル)−9H−プリン−8−イル]−4−フルオロ−フェニル}−メタノール;
8−(1H−インドール−4−イル)−6−((R)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン;
8−(1H−インドール−6−イル)−6−((R)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン;
8−(1H−インドール−4−イル)−2,6−ビス−((S)−3−メチル−モルホリン−4−イル)−9H−プリン;
8−(1H−インドール−4−イル)−6−((S)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン;
8−(1H−インドール−6−イル)−6−((S)−3−メチル−モルホリン−4−イル)−2−モルホリン−4−イル−9H−プリン;
8−(1H−インドール−4−イル)−2−(4−メトキシ−ピペリジン−1−イル)−6−モルホリン−4−イル−9H−プリン;
8−(1H−インドール−4−イル)−2,6−ジ−モルホリン−4−イル−9H−プリン;
8−(1H−インダゾール−4−イル)−2,6−ジ−モルホリン−4−イル−9H−プリン;
8−(1H−インドール−6−イル)−2,6−ジ−モルホリン−4−イル−9H−プリン;
3−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−フェニルアミン;
N−[3−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−フェニル]−アセトアミド;
8−(2−メチル−1H−インドール−4−イル)−2,6−ジ−モルホリン−4−イル−9H−プリン;
3−[2−((2S,6R)−2,6−ジメチル−モルホリン−4−イル)−6−モルホリン−4−イル−9H−プリン−8−イル]−フェニルアミン;
N−[3−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−フェニル]−メタンスルホンアミド;
{2−[2−((2S,6R)−2,6−ジメチル−モルホリン−4−イル)−6−モルホリン−4−イル−9H−プリン−8−イル]−フェニル}−メタノール;
[2−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−フェニル]−メタノール;
3−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−フェノール;
[3−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−フェニル]−メタノール;
2−(2,6−ジ−モルホリン−4−イル−9H−プリン−8−イル)−フェノール;
6−(3,3−ジメチル−モルホリン−4−イル)−8−(1H−インドール−6−イル)−2−モルホリン−4−イル−9H−プリン;
6−(3,3−ジメチル−モルホリン−4−イル)−8−(1H−インドール−4−イル)−2−モルホリン−4−イル−9H−プリン;
8−(2,3−ジヒドロ−1H−インドール−4−イル)−2−((S)−3−メチル−モルホリン−4−イル)−6−((R)−3−メチル−モルホリン−4−イル)−9H−プリン;
8−(2,3−ジヒドロ−1H−インドール−4−イル)−2,6−ビス−((R)−3−メチル−モルホリン−4−イル)−9H−プリン;
8−(1H−インドール−4−イル)−2−((S)−3−メチル−モルホリン−4−イル)−6−((R)−3−メチル−モルホリン−4−イル)−9H−プリン;
8−(1H−インドール−6−イル)−2−((S)−3−メチル−モルホリン−4−イル)−6−((R)−3−メチル−モルホリン−4−イル)−9H−プリン;
8−(1H−インドール−6−イル)−2,6−ビス−((R)−3−メチル−モルホリン−4−イル)−9H−プリン;
8−(1H−インドール−4−イル)−6−((R)−3−メチル−モルホリン−4−イル)−2−(8−オキサ−3−アザ−ビシクロ[3.2.1]オクト−3−イル)−9H−プリン;
8−(1H−インドール−4−イル)−2−((R)−3−メチル−モルホリン−4−イル)−6−モルホリン−4−イル−9H−プリン;
8−(1H−インドール−6−イル)−2−モルホリン−4−イル−6−(1S,4S)−2−オキサ−5−アザ−ビシクロ[2.2.1]ヘプト−5−イル−9H−プリン;
8−(1H−インドール−4−イル)−2−((S)−3−メチル−モルホリン−4−イル)−6−モルホリン−4−イル−9H−プリン;
8−(1H−インドール−4−イル)−2−モルホリン−4−イル−6−(1S,4S)−2−オキサ−5−アザ−ビシクロ[2.2.1]ヘプト−5−イル−9H−プリン;
8−(1H−インドール−6−イル)−6−((S)−3−メチル−モルホリン−4−イル)−2−(8−オキサ−3−アザ−ビシクロ[3.2.1]オクト−3−イル)−9H−プリン;
8−(1H−インドール−4−イル)−6−((S)−3−メチル−モルホリン−4−イル)−2−(8−オキサ−3−アザ−ビシクロ[3.2.1]オクト−3−イル)−9H−プリン;
8−(1H−インドール−6−イル)−2−モルホリン−4−イル−6−(3−オキサ−8−アザ−ビシクロ[3.2.1]オクト−8−イル)−9H−プリン;
8−(1H−インドール−4−イル)−2−モルホリン−4−イル−6−(3−オキサ−8−アザ−ビシクロ[3.2.1]オクト−8−イル)−9H−プリン;
6−(1H−インドール−4−イル)−4−((R)−3−メチル−モルホリン−4−イル)−2−((S)−3−メチル−モルホリン−4−イル)−7H−ピロロ[2,3−d]ピリミジン;
6−(1H−インドール−4−イル)−2,4−ジ−モルホリン−4−イル−7H−ピロロ[2,3−d]ピリミジン
から選択される、請求項1または2に記載の化合物、またはその薬学的に許容される塩。 3- [2-((2S, 6R) -2,6-dimethyl-morpholin-4-yl) -6-morpholin-4-yl-9H-purin-8-yl] -phenol;
3- (2,4-dimorpholino-7H-pyrrolo [2,3-d] pyrimidin-6-yl) phenol;
2,6-bis-((S) -3-methyl-morpholin-4-yl) -8- (1H-pyrrolo [2,3-b] pyridin-4-yl) -9H-purine;
{2-fluoro-5- [6-((S) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purin-8-yl] -phenyl} -methanol;
2- (4,4-difluoro-piperidin-1-yl) -8- (1H-indol-4-yl) -6-((S) -3-methyl-morpholin-4-yl) -9H-purine;
5- [2,6-bis-((S) -3-methyl-morpholin-4-yl) -9H-purin-8-yl] -1,3-dihydro-benzimidazol-2-one;
{5- [2,6-bis-((S) -3-methyl-morpholin-4-yl) -9H-purin-8-yl] -2-methoxy-phenyl} -methanol;
8- (1H-indol-4-yl) -2-morpholin-4-yl-6- (8-oxa-3-aza-bicyclo [3.2.1] oct-3-yl) -9H-purine;
2-methoxy-5- [6-((S) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purin-8-yl] -benzoic acid;
{4-chloro-3- [6-((S) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purin-8-yl] -phenyl} -methanol;
3- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -benzylamine;
1- {3- [6-((S) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purin-8-yl] -phenyl} -ethanol;
2,6-di-morpholin-4-yl-8- (1H-pyrrolo [3,2-b] pyridin-6-yl) -9H-purine;
8- (1H-indol-6-yl) -2,6-bis-((S) -3-methyl-morpholin-4-yl) -9H-purine;
8- (1H-indol-4-yl) -2,6-bis-((R) -3-methyl-morpholin-4-yl) -9H-purine;
1- [8- (1H-indol-4-yl) -6-((S) -3-methyl-morpholin-4-yl) -9H-purin-2-yl] -piperidin-4-ol;
{3- [2,6-bis-((S) -3-methyl-morpholin-4-yl) -9H-purin-8-yl] -5-methoxy-phenyl} -methanol;
8- (1H-Indol-4-yl) -2-((R) -3-methyl-morpholin-4-yl) -6-((S) -3-methyl-morpholin-4-yl) -9H- Pudding;
{3- [2,6-bis-((R) -3-methyl-morpholin-4-yl) -9H-purin-8-yl] -4-fluoro-phenyl} -methanol;
8- (1H-indol-4-yl) -6-((R) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purine;
8- (1H-indol-6-yl) -6-((R) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purine;
8- (1H-indol-4-yl) -2,6-bis-((S) -3-methyl-morpholin-4-yl) -9H-purine;
8- (1H-indol-4-yl) -6-((S) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purine;
8- (1H-indol-6-yl) -6-((S) -3-methyl-morpholin-4-yl) -2-morpholin-4-yl-9H-purine;
8- (1H-indol-4-yl) -2- (4-methoxy-piperidin-1-yl) -6-morpholin-4-yl-9H-purine;
8- (1H-indol-4-yl) -2,6-di-morpholin-4-yl-9H-purine;
8- (1H-indazol-4-yl) -2,6-di-morpholin-4-yl-9H-purine;
8- (1H-indol-6-yl) -2,6-di-morpholin-4-yl-9H-purine;
3- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -phenylamine;
N- [3- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -phenyl] -acetamide;
8- (2-methyl-1H-indol-4-yl) -2,6-di-morpholin-4-yl-9H-purine;
3- [2-((2S, 6R) -2,6-dimethyl-morpholin-4-yl) -6-morpholin-4-yl-9H-purin-8-yl] -phenylamine;
N- [3- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -phenyl] -methanesulfonamide;
{2- [2-((2S, 6R) -2,6-dimethyl-morpholin-4-yl) -6-morpholin-4-yl-9H-purin-8-yl] -phenyl} -methanol;
[2- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -phenyl] -methanol;
3- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -phenol;
[3- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -phenyl] -methanol;
2- (2,6-di-morpholin-4-yl-9H-purin-8-yl) -phenol;
6- (3,3-Dimethyl-morpholin-4-yl) -8- (1H-indol-6-yl) -2-morpholin-4-yl-9H-purine;
6- (3,3-Dimethyl-morpholin-4-yl) -8- (1H-indol-4-yl) -2-morpholin-4-yl-9H-purine;
8- (2,3-Dihydro-1H-indol-4-yl) -2-((S) -3-methyl-morpholin-4-yl) -6-((R) -3-methyl-morpholine-4 -Yl) -9H-purine;
8- (2,3-dihydro-1H-indol-4-yl) -2,6-bis-((R) -3-methyl-morpholin-4-yl) -9H-purine;
8- (1H-Indol-4-yl) -2-((S) -3-methyl-morpholin-4-yl) -6-((R) -3-methyl-morpholin-4-yl) -9H- Pudding;
8- (1H-Indol-6-yl) -2-((S) -3-methyl-morpholin-4-yl) -6-((R) -3-methyl-morpholin-4-yl) -9H- Pudding;
8- (1H-indol-6-yl) -2,6-bis-((R) -3-methyl-morpholin-4-yl) -9H-purine;
8- (1H-Indol-4-yl) -6-((R) -3-methyl-morpholin-4-yl) -2- (8-oxa-3-aza-bicyclo [3.2.1] oct -3-yl) -9H-purine;
8- (1H-indol-4-yl) -2-((R) -3-methyl-morpholin-4-yl) -6-morpholin-4-yl-9H-purine;
8- (1H-Indol-6-yl) -2-morpholin-4-yl-6- (1S, 4S) -2-oxa-5-aza-bicyclo [2.2.1] hept-5-yl- 9H-purine;
8- (1H-indol-4-yl) -2-((S) -3-methyl-morpholin-4-yl) -6-morpholin-4-yl-9H-purine;
8- (1H-Indol-4-yl) -2-morpholin-4-yl-6- (1S, 4S) -2-oxa-5-aza-bicyclo [2.2.1] hept-5-yl- 9H-purine;
8- (1H-Indol-6-yl) -6-((S) -3-methyl-morpholin-4-yl) -2- (8-oxa-3-aza-bicyclo [3.2.1] oct -3-yl) -9H-purine;
8- (1H-Indol-4-yl) -6-((S) -3-methyl-morpholin-4-yl) -2- (8-oxa-3-aza-bicyclo [3.2.1] oct -3-yl) -9H-purine;
8- (1H-indol-6-yl) -2-morpholin-4-yl-6- (3-oxa-8-aza-bicyclo [3.2.1] oct-8-yl) -9H-purine;
8- (1H-indol-4-yl) -2-morpholin-4-yl-6- (3-oxa-8-aza-bicyclo [3.2.1] oct-8-yl) -9H-purine;
6- (1H-Indol-4-yl) -4-((R) -3-methyl-morpholin-4-yl) -2-((S) -3-methyl-morpholin-4-yl) -7H- Pyrrolo [2,3-d] pyrimidine;
3. A compound according to claim 1 or 2 selected from 6- (1H-indol-4-yl) -2,4-di-morpholin-4-yl-7H-pyrrolo [2,3-d] pyrimidine, Or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161437956P | 2011-01-31 | 2011-01-31 | |
US61/437,956 | 2011-01-31 | ||
US201161552905P | 2011-10-28 | 2011-10-28 | |
US61/552,905 | 2011-10-28 | ||
PCT/IB2012/050428 WO2012104776A1 (en) | 2011-01-31 | 2012-01-30 | Novel heterocyclic derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014505696A JP2014505696A (en) | 2014-03-06 |
JP2014505696A5 true JP2014505696A5 (en) | 2015-03-05 |
JP5963777B2 JP5963777B2 (en) | 2016-08-03 |
Family
ID=45607319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013551000A Expired - Fee Related JP5963777B2 (en) | 2011-01-31 | 2012-01-30 | New heterocyclic derivatives |
Country Status (24)
Country | Link |
---|---|
US (2) | US8987257B2 (en) |
EP (1) | EP2670753B1 (en) |
JP (1) | JP5963777B2 (en) |
KR (1) | KR101928116B1 (en) |
CN (1) | CN103476777B (en) |
AP (1) | AP2013007043A0 (en) |
AR (1) | AR085039A1 (en) |
AU (1) | AU2012213080B2 (en) |
BR (1) | BR112013019509A2 (en) |
CA (1) | CA2825605C (en) |
CL (1) | CL2013002177A1 (en) |
CO (1) | CO6781507A2 (en) |
CR (1) | CR20130369A (en) |
EA (1) | EA025011B1 (en) |
ES (1) | ES2611885T3 (en) |
IL (1) | IL227664A0 (en) |
MX (1) | MX343706B (en) |
PE (1) | PE20140293A1 (en) |
PL (1) | PL2670753T3 (en) |
PT (1) | PT2670753T (en) |
SG (1) | SG192193A1 (en) |
TW (1) | TW201309700A (en) |
UY (1) | UY33883A (en) |
WO (1) | WO2012104776A1 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
AP2013007043A0 (en) | 2011-01-31 | 2013-08-31 | Novartis Ag | Novel heterocyclic derivatives |
WO2013061305A1 (en) * | 2011-10-28 | 2013-05-02 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
US10989719B2 (en) * | 2013-10-11 | 2021-04-27 | National University Corporation Tokyo Medical And Dental University | Methods for treating spinocerebellar ataxia type I using RPA1 |
HUE053654T2 (en) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | Combinations of fgfr- and cmet-inhibitors for the treatment of cancer |
RU2715893C2 (en) | 2014-03-26 | 2020-03-04 | Астекс Терапьютикс Лтд | Combination of inhibitor fgfr and inhibitor igf1r |
JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
AU2015240465B2 (en) | 2014-04-04 | 2020-02-27 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
JOP20200201A1 (en) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
EP3828269B1 (en) | 2015-03-06 | 2023-05-03 | Korea Advanced Institute Of Science And Technology | Composition for prevention or treatment of intractable epilepsy comprising mtor inhibitor |
JP6669417B2 (en) | 2015-03-30 | 2020-03-18 | 第一三共株式会社 | 6-morpholinyl-2-pyrazolyl-9H-purine derivatives and their use as PI3K inhibitors |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
SI3353177T1 (en) | 2015-09-23 | 2020-08-31 | Janssen Pharmaceutica Nv | Tricyclic heterocycles for the treatment of cancer |
EP3353164B1 (en) | 2015-09-23 | 2021-11-03 | Janssen Pharmaceutica, N.V. | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
EP3550018B1 (en) | 2016-12-02 | 2022-03-09 | Daiichi Sankyo Company, Limited | NOVEL ENDO-ß-N-ACETYLGLUCOSAMINIDASE |
CZ308800B6 (en) * | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyclic nitrogenous derivatives of purine, pharmaceutical preparations containing these derivatives and their use in neuroprotection |
EP4161519A1 (en) * | 2020-06-03 | 2023-04-12 | Yumanity Therapeutics, Inc. | Purines and methods of their use |
WO2023107552A2 (en) * | 2021-12-08 | 2023-06-15 | Kineta, Inc. | Purines and methods of their use |
CN115181100A (en) * | 2022-07-27 | 2022-10-14 | 广西大学 | Sulfonamide micromolecule inhibitor with purine and pyrrolopyrimidine parent nucleus |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB864145A (en) * | 1959-06-02 | 1961-03-29 | Thomae Gmbh Dr K | Novel purines and a process for their manufacture |
US3016378A (en) * | 1959-07-01 | 1962-01-09 | Thomae Gmbh Dr K | Amino-substituted purine derivatives |
JPS6041077B2 (en) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | Cis platinum(2) complex of 1,2-diaminocyclohexane isomer |
US4323581A (en) | 1978-07-31 | 1982-04-06 | Johnson & Johnson | Method of treating carcinogenesis |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
EP0303697B1 (en) | 1987-03-09 | 1997-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance k-252 |
US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
JP2766360B2 (en) | 1988-02-04 | 1998-06-18 | 協和醗酵工業株式会社 | Staurosporine derivative |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
AU2866992A (en) | 1991-10-10 | 1993-05-03 | Schering Corporation | 4'-(n-substituted-n-oxide)staurosporine derivatives |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
JPH07505124A (en) | 1991-11-08 | 1995-06-08 | ザ ユニバーシティ オブ サザン カリフォルニア | Composition containing K-252 compound for enhancing neurotrophin activity |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5948898A (en) | 1992-03-16 | 1999-09-07 | Isis Pharmaceuticals, Inc. | Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
PL175327B1 (en) * | 1992-04-03 | 1998-12-31 | Upjohn Co | Bicyclic heterocyclic amines |
US5756494A (en) | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
US5621100A (en) | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
JP3608788B2 (en) | 1992-08-31 | 2005-01-12 | ルドヴィグ・インスティテュート・フォー・キャンサー・リサーチ | Isolated nonapeptides derived from the MAGE-3 gene and presented by HLA-A1 and their uses |
DE69331228D1 (en) | 1992-09-21 | 2002-01-10 | Kyowa Hakko Kogyo Kk | Heilmittel für thrombozytopenia |
CA2145985C (en) | 1992-10-28 | 2003-09-16 | Napoleone Ferrara | Vascular endothelial cell growth factor antagonists |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
JPH09500128A (en) | 1993-07-15 | 1997-01-07 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | Imidazo [4,5-c] pyridin-4-amine |
US5478932A (en) | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
AU1339895A (en) | 1993-12-23 | 1995-07-10 | Eli Lilly And Company | Protein kinase c inhibitors |
US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
EP2295415A1 (en) | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
WO1997007081A2 (en) | 1995-08-11 | 1997-02-27 | Yale University | Glycosylated indolocarbazole synthesis |
FR2741881B1 (en) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | NOVEL PURINE DERIVATIVES HAVING IN PARTICULAR ANTI-PROLIFERATIVE PRORIETES AND THEIR BIOLOGICAL APPLICATIONS |
CA2231105C (en) | 1995-12-08 | 2005-09-13 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives |
KR100447918B1 (en) | 1996-07-25 | 2005-09-28 | 동아제약주식회사 | Flavones and flavanone compounds with protective gastrointestinal tract including large intestine |
IL128124A0 (en) | 1996-08-02 | 1999-11-30 | Genesense Technologies Inc | Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase |
CO4950519A1 (en) | 1997-02-13 | 2000-09-01 | Novartis Ag | PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION |
US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
CA2294244A1 (en) | 1997-07-12 | 1999-01-21 | Cancer Research Campaign Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
HUP0103617A2 (en) | 1998-05-29 | 2002-02-28 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors, pharmaceutical compositions containing the compounds and their use |
US20030083242A1 (en) | 1998-11-06 | 2003-05-01 | Alphonse Galdes | Methods and compositions for treating or preventing peripheral neuropathies |
EP1189641B1 (en) | 1999-06-25 | 2009-07-29 | Genentech, Inc. | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
CA2379035A1 (en) | 1999-07-13 | 2001-01-18 | Shiro Akinaga | Staurosporin derivatives |
UA72946C2 (en) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Quinasoline derivatives as inhibitors of vascular endothelial growth factor (vegf) |
CA2399358C (en) | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
WO2001079255A1 (en) | 2000-04-12 | 2001-10-25 | Genaera Corporation | A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group |
IL153111A0 (en) | 2000-06-30 | 2003-06-24 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
KR100732206B1 (en) | 2000-09-11 | 2007-06-27 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | Quinolinone derivatives as tyrosine kinase inhibitors |
US6677450B2 (en) | 2000-10-06 | 2004-01-13 | Bristol-Myers Squibb Company | Topoisomerase inhibitors |
JP4323167B2 (en) | 2001-01-16 | 2009-09-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Isolation of cells expressing secreted proteins |
WO2002062826A1 (en) | 2001-02-07 | 2002-08-15 | Vadim Viktorovich Novikov | Method for producing peptides |
WO2003004505A1 (en) | 2001-07-02 | 2003-01-16 | Debiopharm S.A. | Oxaliplatin active substance with a very low content of oxalic acid |
KR100484504B1 (en) | 2001-09-18 | 2005-04-20 | 학교법인 포항공과대학교 | Inclusion compound comprising curcurbituril derivatives as host molecule and pharmaceutical composition comprising the same |
US20030134846A1 (en) | 2001-10-09 | 2003-07-17 | Schering Corporation | Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors |
EP1485082A4 (en) | 2002-02-19 | 2009-12-30 | Xenoport Inc | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
DE60329910D1 (en) | 2002-03-29 | 2009-12-17 | Novartis Vaccines & Diagnostic | SUBSTITUTED BENZAZOLE AND THEIR USE AS RAF KINASE HEMMER |
US6727272B1 (en) | 2002-07-15 | 2004-04-27 | Unitech Pharmaceuticals, Inc. | Leflunomide analogs for treating rheumatoid arthritis |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
AU2003300021A1 (en) | 2002-12-27 | 2004-07-29 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
WO2004064759A2 (en) | 2003-01-21 | 2004-08-05 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
JP2007524596A (en) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | Co-crystal pharmaceutical composition |
US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
WO2006128172A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating b cell regulated autoimmune disorders |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
WO2010002954A1 (en) * | 2008-07-02 | 2010-01-07 | Wyeth | (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
CA2740389A1 (en) | 2008-10-15 | 2010-05-20 | Gilead Sciences, Inc. | 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors |
BRPI0921156A2 (en) * | 2008-11-11 | 2016-02-23 | Xcovery Holding Co Llc | pi3k / mtor kinase inhibitors |
WO2011025889A1 (en) | 2009-08-28 | 2011-03-03 | Takeda Pharmaceutical Company Limited | HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS |
EP2498780B1 (en) | 2009-11-12 | 2016-09-07 | F.Hoffmann-La Roche Ag | N-9-substituted purine compounds, compositions and methods of use |
RU2515541C2 (en) | 2009-11-12 | 2014-05-10 | Ф.Хоффманн-Ля Рош Аг | N-7 substituted purines and pyrazolopyrimidines, compositions thereof and methods for use |
WO2011078795A1 (en) | 2009-12-21 | 2011-06-30 | S*Bio Pte Ltd | Bridged morpholino substituted purines |
AR083267A1 (en) | 2010-10-04 | 2013-02-13 | Novartis Ag | PHARMACEUTICAL COMBINATIONS |
AP2013007043A0 (en) | 2011-01-31 | 2013-08-31 | Novartis Ag | Novel heterocyclic derivatives |
CN103650345A (en) | 2011-07-22 | 2014-03-19 | 辉达公司 | Component analysis systems and methods |
WO2013061305A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
-
2012
- 2012-01-30 AP AP2013007043A patent/AP2013007043A0/en unknown
- 2012-01-30 AR ARP120100296A patent/AR085039A1/en not_active Application Discontinuation
- 2012-01-30 PT PT127041358T patent/PT2670753T/en unknown
- 2012-01-30 AU AU2012213080A patent/AU2012213080B2/en not_active Ceased
- 2012-01-30 PE PE2013001714A patent/PE20140293A1/en not_active Application Discontinuation
- 2012-01-30 KR KR1020137022750A patent/KR101928116B1/en active IP Right Grant
- 2012-01-30 BR BR112013019509A patent/BR112013019509A2/en not_active Application Discontinuation
- 2012-01-30 US US13/361,365 patent/US8987257B2/en not_active Expired - Fee Related
- 2012-01-30 EA EA201391106A patent/EA025011B1/en not_active IP Right Cessation
- 2012-01-30 MX MX2013008795A patent/MX343706B/en active IP Right Grant
- 2012-01-30 SG SG2013057492A patent/SG192193A1/en unknown
- 2012-01-30 UY UY0001033883A patent/UY33883A/en not_active Application Discontinuation
- 2012-01-30 ES ES12704135.8T patent/ES2611885T3/en active Active
- 2012-01-30 PL PL12704135T patent/PL2670753T3/en unknown
- 2012-01-30 JP JP2013551000A patent/JP5963777B2/en not_active Expired - Fee Related
- 2012-01-30 EP EP12704135.8A patent/EP2670753B1/en active Active
- 2012-01-30 CA CA2825605A patent/CA2825605C/en not_active Expired - Fee Related
- 2012-01-30 TW TW101102924A patent/TW201309700A/en unknown
- 2012-01-30 CN CN201280014339.6A patent/CN103476777B/en not_active Expired - Fee Related
- 2012-01-30 WO PCT/IB2012/050428 patent/WO2012104776A1/en active Application Filing
-
2013
- 2013-07-25 IL IL227664A patent/IL227664A0/en unknown
- 2013-07-29 CO CO13179136A patent/CO6781507A2/en not_active Application Discontinuation
- 2013-07-30 CL CL2013002177A patent/CL2013002177A1/en unknown
- 2013-07-31 CR CR20130369A patent/CR20130369A/en unknown
-
2015
- 2015-03-11 US US14/644,953 patent/US9458163B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014505696A5 (en) | ||
JP6862495B2 (en) | Treatment of B-cell malignancies with a combination of JAK and PI3K inhibitors | |
JP2014521725A5 (en) | ||
KR102350088B1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
JP2013529196A5 (en) | ||
JP2020530496A5 (en) | ||
ES2531465T3 (en) | Pyrimidinone derivatives, their preparation and pharmaceutical use | |
TW202028204A (en) | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | |
KR20150128839A (en) | Heterocyclic compounds and uses thereof | |
JP2014511893A5 (en) | ||
JP2008517913A5 (en) | ||
JP2017520613A5 (en) | ||
EP2650293A8 (en) | [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof | |
JP2013508382A5 (en) | ||
RU2017105353A (en) | COMPOUNDS | |
JP2013508382A (en) | AKT inhibitor | |
AU2023203088A1 (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors | |
CN112119072A (en) | Compounds and methods for IDO and TDO modulation, and indications thereof | |
CN114599361A (en) | Pharmaceutical compositions of PRMT5 inhibitors | |
JP2018534314A5 (en) | ||
RU2014109748A (en) | MORPHOLIN-SUBSTITUTED DERIVATIVES OF Bicyclic Pyrimidine Urea or Carbamate as MTOR Inhibitors | |
RU2014131367A (en) | Thienopyrimidine Compounds | |
EP4017590A1 (en) | Pyrazolo[4,3-c]pyridine derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
US20220235048A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
JP2009525292A5 (en) |